Tradestie Institutional Equity Comparison Engine
OSRH vs IBO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBO Overall Edge
IBO Captures Institutional Edge (3โ0 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, OSRH trades at N/M Forward P/E with -960.8% operating margin (-72.2% YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, OSRH sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
IBO
OSRH N/M vs IBO N/M Fwd P/E
Growth & Margin Winner
IBO
Op Margin -960.8% vs -12621.0% ยท YoY -72.2% vs +16.7%
Momentum & Technical Winner
IBO
1Y -77.4% vs +862.8% ยท 52W Pos 3% vs 67%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
OSRH
NASDAQ
OSR Holdings, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.12
-53.4% 1D
Market Cap
$8.8M
1M Return
-73.1%
1Y Return
-77.38%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 33.0
Fund 46.0
Flow 50.0
Mom 60.0
IBO
NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap
$44.4M
1M Return
+83.21%
1Y Return
+862.75%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OSRH -77.38%
IBO +862.75%
Spread: +69.62 pp (IBO Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OSRH Revenue | IBO Revenue | OSRH Op. Margin | IBO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2022 | N/A | $0M | N/A | -6808.0% | IBO |
| FY2024 | $0M | N/A | -331.2% | N/A | OSRH |
| FY2025 | $0M | $0M | -631.0% | -13381.2% | OSRH |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OSRH | IBO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $8.8M | $44.4M | Larger Scale | IBO |
| Trailing P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | IBO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -72.2% | +16.7% | Higher Growth | IBO |
| Operating Margin (TTM) Profitability | -960.8% | -12621.0% | Higher Margin | OSRH |
| Net Profit Margin Profitability | 0.0% | 4247.4% | Higher Margin | IBO |
| Return on Equity (ROE) Capital Efficiency | -11.3% | 71.2% | Higher ROE | IBO |
| 52-Week Range Position Momentum | 3% ($0โ$1) | 67% ($0โ$7) | Stronger Trend | IBO |
| Beta / 30D Volatility Risk Regime | 0.57ฮฒ ยท 390% Vol | -6.72ฮฒ ยท 120% Vol | Lower Realized Risk | IBO |
| Unified Institutional Score Composite Signal | 45.0 / 100 (HOLD) | 36.8 / 100 (SELL) | Higher Composite | OSRH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OSRH vs IBO Buy Guide
OSRH
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IBO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OSRH nor IBO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.